Iqvia Holdings Inc.
IQVQ4 2025(IQV Q3 FY2025)Estimated4.5% AI
AI Revenue %
4.5%
AI Fair Value
$986.6M
AI Revenue (Q)
$515.1M
Total Revenue (Q)
$11.4B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
No AI revenue breakout. TAS segment was $1,631M (39.8% of $4,100M total). Maintaining AI penetration estimate of ~11% of TAS = ~$179M, or ~4.4% of total. Rounded to 4.5%. Nine-month TAS was $4,805M out of $11,946M total (40.2%). IQVIA now has ~91,000 employees and continues expanding AI capabilities, but the absence of any specific AI revenue disclosure limits confidence.
Analyzed by claude-opus-4-6
Quoted Figures
Technology & Analytics Solutions revenues $1,631M; Total revenues $4,100M for Q3 2025
10-Q filed 2025-09-30, Segment Data
Nine Months TAS revenues $4,805M; Nine Months Total revenues $11,946M
10-Q filed 2025-09-30, Segment Data
AI Products Identified (Ring 1)
IQVIA Connected Intelligence (Healthcare-grade AI)AI-powered clinical trial optimizationAI-driven real world evidence analyticsAI-enhanced commercial analyticsOrchestrated Clinical Trials (AI-enabled)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Traditional data subscriptionsLegacy analytics platformsClinical research services (non-AI CRO)Contract sales and medical solutions
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix